Skip to main content

J.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Tipranks - Tipranks - Thu May 8, 2025

J.P. Morgan analyst Anupam Rama maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of $11.00.

Protect Your Portfolio Against Market Uncertainty

According to TipRanks, Rama is an analyst with an average return of -3.9% and a 39.80% success rate. Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, BridgeBio Pharma, and Neurocrine.

In addition to J.P. Morgan, SAGE Therapeutics also received a Hold from Truist Financial’s Joon Lee in a report issued on May 5. However, on April 30, Scotiabank maintained a Buy rating on SAGE Therapeutics (NASDAQ: SAGE).

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $13.47 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.31M.

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).